The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Paclitaxel-carboplatin (P-C) regimen for metastatic breast cancer (MBC): Single-institution retrospective evaluation.
M. Zambetti
No relevant relationships to disclose
G. Goisis
No relevant relationships to disclose
A. Moliterni
No relevant relationships to disclose
A. Marchianò
No relevant relationships to disclose
D. Scaramuzza
No relevant relationships to disclose
M. L. Carcangiu
No relevant relationships to disclose
G. Saibene
No relevant relationships to disclose
G. Mariani
No relevant relationships to disclose
G. V. Bianchi
No relevant relationships to disclose
P. Valagussa
No relevant relationships to disclose
L. Gianni
No relevant relationships to disclose